With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Novartis’ new CEO Vas Narasimhan has shown his priorities by promoting the company’s digital chief to the executive committee. New broom and chief digital officer Bertrand Bodson has been ...

CEO Vas Narasimhan said the company has more than 25 potential blockbusters in its pipeline. Psoriasis drug Cosentyx and heart failure drug Entresto are leading the charge among the company’s ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal with groundbreaking gene therapy company Spark Therapeutics ...

“Therefore, I decided to accept a new role as CEO of a US-based biotech. I want to thank [CEO Vas Narasimhan] for the opportunity to work at this great company and to everyone in oncology for ...

As it stands, Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US, although Novartis chief executive Vas Narasimhan said this morning he ...

Novartis has announced a five-year commitment to the fight against malaria, saying it plans to invest more than $100m to advance R&D of next-generation drugs for the disease becomes resistant to ...